Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Journal of the American College of Cardiologists, June 2025

While pulmonary endarterectomy (PEA) is the primary treatment in chronic thromboembolic pulmonary hypertension (CTEPH), it is not feasible for at least 40% of patients. Balloon pulmonary angioplasty (BPA) has emerged as an alternative for these patients.The International Balloon Pulmonary Angioplasty (BPA) Registry aimed to assess practices and outcomes across 18 centers in the U.S., Europe, […]

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Journal of the American College of Cardiologists, June 2025 Read Post »

The pulmonary arterial hypertension (PAH) patient perspective, International Journal of Cardiology Congenital Heart Disease, September 2025 edition

This article titled “The pulmonary arterial hypertension patient perspective”, explores the experiences of patients living with pulmonary arterial hypertension associated with Congenital Heart Disease (PAH-CHD). Thanks to medical advances, many individuals with congenital heart disease are now living longer, but face numerous challenges including physical limitations, mental health issues, relationship strains, financial burdens, and family

The pulmonary arterial hypertension (PAH) patient perspective, International Journal of Cardiology Congenital Heart Disease, September 2025 edition Read Post »

A randomized controlled trial of self-help cognitive behavioural therapy for depression in adults with pulmonary hypertension, British Journal of Health Psychology, September 2025 edition

A study of self-help cognitive behavioural therapy for depression in adults with pulmonary hypertension was recently conducted by a group of researchers and published in the British Journal of Health Psychology. Using a randomized controlled trial design with a wait-list control group, 68 adults reporting depressive symptoms were recruited from global pulmonary hypertension associations. The

A randomized controlled trial of self-help cognitive behavioural therapy for depression in adults with pulmonary hypertension, British Journal of Health Psychology, September 2025 edition Read Post »

Major Study Shows Sotatercept Helps High-Risk Pulmonary Arterial Hypertension Patients, New England Journal of Medicine, May 29, 2025

This study focused on some of the sickest pulmonary arterial hypertension patients – those with advanced disease who were already on the best available treatments but still faced a high risk of dying within the next year. For these patients, doctors have traditionally had limited options. Researchers enrolled 172 high-risk patients who were already receiving

Major Study Shows Sotatercept Helps High-Risk Pulmonary Arterial Hypertension Patients, New England Journal of Medicine, May 29, 2025 Read Post »

Recording of May 15, 2025 European Patients’ Forum webinar on understanding patients’ rights in the European Health Data Space (EHDS) now available

On 15 May 2025, the European Patient Forum (EPF) hosted a webinar to inform patients, health professionals, researchers, and other stakeholders about the key aspects of the European Health Data Space (EHDS). The webinar focused on patients’ rights and the practical changes the regulation introduces. The recording is now available at this link Photo credit:

Recording of May 15, 2025 European Patients’ Forum webinar on understanding patients’ rights in the European Health Data Space (EHDS) now available Read Post »

The Role of Telehealth in Pulmonary Arterial Hypertension (PAH) Management: Benefits, Barriers, and Solutions, Pulmonary Circulation, June 9, 2025

The use of remote healthcare services expanded significantly during the COVID-19 pandemic, promoting distant patient care management. Telehealth may be effective in managing patients with pulmonary arterial hypertension (PAH), due to its use in the management of other chronic diseases. However, evidence for telehealth use in pulmonary arterial hypertension is limited to a few small

The Role of Telehealth in Pulmonary Arterial Hypertension (PAH) Management: Benefits, Barriers, and Solutions, Pulmonary Circulation, June 9, 2025 Read Post »

Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials, a systematic review and metanalysis, European Respiratory Review, May 14, 2025

Health-related quality of life (HRQoL ) is an important outcome measure in pulmonary arterial hypertension research, but an evaluation of which patient questionnaires work best had not been done up to now. Also, different studies use different questionnaires, making it hard to compare results. A systematic review (PROSPERO ID: CRD42024484021) was conducted following Preferred Reporting

Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials, a systematic review and metanalysis, European Respiratory Review, May 14, 2025 Read Post »

A new Phase 2b trial on treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH) shows very promising results, INSMED

TPIP is a new version of an existing pulmonary arterial hypertension medication called treprostinil. It is designed as a “prodrug” – meaning it becomes active only after the body processes it. The key advantage is that TPIP can be taken as a dry powder in a capsule-based inhaler, once daily. In a 102-patient phase 2b

A new Phase 2b trial on treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH) shows very promising results, INSMED Read Post »

Scientists Find Four Types of Pulmonary Hypertension Using Blood Protein Patterns, American Journal of Respiratory and Critical Care Medicine, May 9, 2025

Patients with pulmonary hypertension are classified according to clinical criteria to inform treatment decisions. Knowledge of the molecular drivers of pulmonary hypertension might better inform treatment choice, say researchers involved in a study published in May in the American Journal of Respiratory and Critical Care Medicine. The researchers studied blood samples from 470 people who

Scientists Find Four Types of Pulmonary Hypertension Using Blood Protein Patterns, American Journal of Respiratory and Critical Care Medicine, May 9, 2025 Read Post »

Lung Transplantation Updates: Broader Indications with a Focus on Pulmonary arterial Hypertension, Zentralblatt für Chirurgie, May 15, 2025.

In their recent open-access article for the Zentralblatt für Chirurgie, Drs.: Szofia Kovacs, Alberto Benazzo, and Peter Jaksch review the latest International Society for Lung and Heart Transplantion (ISHLT) guidelines on lung transplantation, highlighting a major shift toward personalized, inclusive care. Beyond the underlying lung disease, transplant decisions now consider age, frailty, comorbidities, and psychosocial

Lung Transplantation Updates: Broader Indications with a Focus on Pulmonary arterial Hypertension, Zentralblatt für Chirurgie, May 15, 2025. Read Post »

Timing Matters: When Should Pulmonary Arterial Hypertension Patients Be Referred for Lung Transplantation? Current Opinion in Pulmonary Medicine, July 1 2025 edition

Early referral for lung transplantation can be life-saving for people with pulmonary arterial hypertension (PAH). In this important review, van der Ploeg et al. explore when and how patients across major respiratory diseases especially Pulmonary Arterial Hypertension should be referred for transplant evaluation. As medical therapies continue to improve, the urgency and timing of referral

Timing Matters: When Should Pulmonary Arterial Hypertension Patients Be Referred for Lung Transplantation? Current Opinion in Pulmonary Medicine, July 1 2025 edition Read Post »

The Alliance for Pulmonary Hypertension Joins European Patients’ Forum (EPF) to Help Shape the Future of Patient Advocacy in Europe

Introduction The European Patients’ Forum (EPF) is a leading umbrella organisation that represents the collective interests of patient organisations across Europe. With a strong focus on equity, patient-centred care, and meaningful involvement in health policy and systems, the European Patients’ Forum brings together diverse patient voices to influence European health debates and decision-making. The organisation

The Alliance for Pulmonary Hypertension Joins European Patients’ Forum (EPF) to Help Shape the Future of Patient Advocacy in Europe Read Post »

UK-wide study validates the digital version of the emPHasis-10 QOL questionnaire for pulmonary arterial hypertension patients, European Respiratory Journal, May 2025

The emPHasis-10 questionnaire, designed to reflect that lived experience, has long been a trusted tool in both clinics and studies but until now, it was only available on paper. In a new UK-wide study, researchers led by Dr. Joseph Newman and colleagues tested the first digital version of emPHasis-10 using the Atom5™ smartphone app. Their

UK-wide study validates the digital version of the emPHasis-10 QOL questionnaire for pulmonary arterial hypertension patients, European Respiratory Journal, May 2025 Read Post »

Defining “patient engagement” and distinguishing between individual empowerment and systemic partnership and advocacy, Sara Riggae, May 20 2025

Sarah Riggae is a researcher and educator who suffers from Parkinson’s disease,  In a recent article on her blog she defines what is meant by “patient engagement” and distinguishes between “primary” and “secondary” engagement.  Short summary: Primary Patient Engagement focuses on individual patient empowerment in their own healthcare journey. This includes: It’s essentially about patients having

Defining “patient engagement” and distinguishing between individual empowerment and systemic partnership and advocacy, Sara Riggae, May 20 2025 Read Post »

10-year Data on Oral Selexipag: Long-Term Survival, Safety, and Dosing Insights in Pulmonary Arterial Hypertension (PAH), oral session at ISHLT congress, April 29, 2025 

Selexipag is an oral selective IP prostacyclin receptor agonist. This study, presented during an oral session at the International Society for Heart and Lung Transplant (ISHLT) congress on April 29, 2025, provides the longest follow-up data available for any pulmonary arterial hypertension therapy, tracking 574 patients originally randomized to selexipag in the GRIPHON trial, with

10-year Data on Oral Selexipag: Long-Term Survival, Safety, and Dosing Insights in Pulmonary Arterial Hypertension (PAH), oral session at ISHLT congress, April 29, 2025  Read Post »

Survey uncovers significant emotional and social impacts beyond traditional medical outcomes for women with pulmonary arterial hypertension, Healio, May 19, 2025

Isabella Hornick’s article, “ Women with Pulmonary Arterial Hypertension Report Struggles with Family Planning and Caregiver Needs”, published by Healio on May 19, 2205, reports on comprehensive survey conducted on 275 women with pulmonary arterial hypertension aged 21-50 from the U.S., U.K., Canada, and Germany. The average age of the included women differed at PAH

Survey uncovers significant emotional and social impacts beyond traditional medical outcomes for women with pulmonary arterial hypertension, Healio, May 19, 2025 Read Post »

Cereno Scientific receives endorsement from the US Food and Drug Administration for their Phase IIb trial of CS1 in pulmonary arterial hypertension

The investigational drug CS1 aims to reverse the pathological vascular remodeling of the small pulmonary arteries. A successful Phase IIa trial was concluded in 2024 (see our article here). Insights into the long-term use of CS1 are being gathered in an expanded access program with 10 patients from the Phase IIa trial. Preparations are currently

Cereno Scientific receives endorsement from the US Food and Drug Administration for their Phase IIb trial of CS1 in pulmonary arterial hypertension Read Post »

US Food and Drug Administration approves YUTREPIA, a treprostinil inhalation powder for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease

Yutrepia is a dry powder formulation of treprostinil, a prostacyclin analog. It is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effort. Yutrepia was was tentatively approved by the Food and Drug Administration last year (see our article here), but the agency was waiting for regulatory exclusivity of a competing product

US Food and Drug Administration approves YUTREPIA, a treprostinil inhalation powder for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease Read Post »

Researchers at Imperial College London and Apollo Therapeutics are developing a potential treatment for pulmonary arterial hypertension, David Silverman, Imperial College New, May 5, 2025

Imperial College London is working with Apollo Therapeutics to develop a prospective monoclonal antibody treatment for pulmonary arterial hypertension (PAH). The potential treatment is based on a protein that was identified in original research by the university, and is currently undergoing a proof of concept trial at Hammersmith Hospital, part of Imperial College Healthcare NHS Trust. To

Researchers at Imperial College London and Apollo Therapeutics are developing a potential treatment for pulmonary arterial hypertension, David Silverman, Imperial College New, May 5, 2025 Read Post »

PVRI International Conference 2025 report, Navneet Singh, Katarina Zeder, Pulmonary Circulation, May 1, 2025

An editorial titled “PVRI International Conference 2025: Embracing Heterogeneity”, published in Pulmonary Circulation on May 1, 2025, summarizes the 2025 PVRI International Conference held in Rio de Janeiro, Brazil. The four-day gathering brought together experts from 25 countries across 5 continents to discuss advances in early diagnosis, risk stratification, and treatment approaches for various forms

PVRI International Conference 2025 report, Navneet Singh, Katarina Zeder, Pulmonary Circulation, May 1, 2025 Read Post »

TRANSLATE »
Scroll to Top